doi:10.3969/j.issn.1004-583X.2026.04.015

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.04.015

https://www.lchc.cn/EN/Y2026/V41/I4/380

References 28

[1]	Liu K, Wang BZ, Hao Y, et al. The correlation between migraine and patent foramen ovale[J]. Front Neurol, 11:543485. doi:10.3389/fneur.2020.543485.
[2]	Gollion C, Lerebours F, Barbieux-Guillot M, et al. Cryptogenic ischemic stroke in migraine: Role of patent foramen ovale[J]. Front Pain Res (Lausanne), 3:823595.doi:10.3389/fpain.2022.823595.
[3]	Badea RŞ, Grecu N, Ribigan AC, et al. Headache patterns in patent foramen ovale patients: Beyond migraine with aura[J]. J Neural Transm (Vienna), 2024, 131(7):755-761.doi:10.1007/s00702-024-02760-8.
[4]	Cao W, Shen Y, Zhong J, et al. The Patent foramen ovale and migraine: Associated mechanisms and perspectives from MRI evidence[J]. Brain Sci, 2022, 12(7):941. doi:10.3390/brainsci12070941.
[5]	Zhang Y, Wang H, Liu L. Patent foramen ovale closure for treating migraine: A meta-analysis[J]. J Interv Cardiol, 2022:6456272. doi:10.1155/2022/6456272.
[6]	Zhang QQ, Lu JJ, Yan MY, et al. The efficacy of percutaneous patent foramen ovale closure on migraine: A meta-analysis of randomized controlled trials and observational studies[J]. Biomed Res Int, 2021:6643266. doi:10.1155/2021/6643266.
[7]	Kong R, Yu J, Li J, et al. Transcatheter closure of patent foramen ovale in children with migraine or dizziness[J]. Eur J Pediatr, 2025, 184(9):544. doi:10.1007/s00431-025-06367-3.
[8]	Ben-Assa E, Rengifo-Moreno P, Al-Bawardy R, et al. Effect of residual interatrial shunt on migraine burden after transcatheter closure of patent foramen ovale[J]. JACC Cardiovasc Interv, 2020, 13(3):293-302. doi:10.1016/j.jcin.2019.09.042.
[9]	Ujka K, Pizzuto A, Giordano M, et al. Prevalence, classification, and treatment of residual shunt after patent foramen ovale closure[J]. EuroIntervention, 2025, 21(16):933-941. doi:10.4244/EIJ-D-24-00856. pmid: 40828307
[10]	Nakayama R, Takaya Y, Akagi T, et al. Relationship between patent foramen ovale anatomical features and residual shunt after patent foramen ovale closure[J]. Cardiovasc Interv Ther, 2024, 39(2):200-206. doi:10.1007/s12928-023-00979-y. pmid: 38265606
[11]	Katsianos E, Oikonomou E, Kalogeras K, et al. Residual right-to-left-shunt following transcatheter patent foramen ovale closure: The role of antithrombotic treatment[J]. Curr Pharm Des, 2022, 28(40):3305-3312. doi:10.2174/1381612829666221028095839.
[12]	Deng W, Yin S, McMullin D, et al. Residual shunt after patent foramen ovale closure and long-term stroke recurrence: A prospective cohort study[J]. Ann Intern Med, 2020, 172(11):717-725. doi:10.7326/M19-3583. pmid: 32422058
[13]	Fan JN, Li MF, Zhang BJ, et al. Overlooked trigger of migraine: Clinical significance of small-and medium-shunt patent foramen ovale[J]. Cardiology, 2025, 5:1-10. doi:10.1159/000546696.
[14]	Mi Z, He G, Li C, et al. Efficacy and safety of transesophageal ultrasound-guided patent foramen ovale closure for migraine in adolescents[J]. Front Pediatr, 2023, 11:1296825.doi:10.3389/fped.2023.1296825.
[15]	Qi Y, Zhang Y, Luo X, et al. Efficacy of patent foramen ovale closure for treating migraine: A prospective follow-up study[J]. J Investig Med, 2021, 69(1):7-12. doi:10.1136/jim-2020-001323.
[16]	Witte LS, El Bouziani A, Beijk MAM, et al. Persistence of residual shunt at 6 and 12 months after transoesophageal echocardiography-guided percutaneous closure of a patent foramen ovale for cryptogenic stroke[J]. Heart, 2024, 110(19):1172-1179. doi:10.1136/heartjnl-2024-323905. pmid: 39122559
[17]	Khasiyev F, Arsava EM, Topcuoglu MA. Cerebral vasomotor reactivity in migraine: Effect of patent foramen ovale and aerogenic microembolism[J]. Neurol Res, 2020, 42(9):795-804. doi:10.1080/01616412.2020.1775015. pmid: 32496894
[18]	Fu X, Li M. Relationship between migraine and patent foramen ovale observed by contrast-enhanced transthoracic echocardiography[J]. J Coll Physicians Surg Pak, 2023, 33(3):352-354. doi:10.29271/jcpsp.2023.03.352. pmid: 36945169
[19]	Harm T, Zdanyte M, Goldschmied A, et al. Pre-interventional transesophageal echocardiography as a reliable predictor of residual shunt following patent foramen ovale closure[J]. Clin Res Cardiol, 2026, 115(3):484-494. doi:10.1007/s00392-025-02713-5.
[20]	Perdreau E, Jalal Z, Walton RD, et al. Assessment of nit-occlud atrial septal defect occluder device healing process using micro-computed tomography imaging[J]. PLoS One, 2023, 18(4):e0284471. doi:10.1371/journal.pone.0284471.
[21]	Dong B, Li X, Zhang L, et al. Effects of patent foramen ovale in migraine: A metabolomics-based study[J]. J Physiol, 2025, 603(4):809-835. doi:10.1113/JP286772.
[22]	Trabattoni D, Brambilla M, Canzano P, et al. Migraine in patients undergoing pfo closure: Characterization of a platelet-associated pathophysiological mechanism: the LEARNER study[J]. JACC Basic Transl Sci, 2022, 7(6):525-540. doi:10.1016/j.jacbts.2022.02.002. pmid: 35818509
[23]	Li C, Yu Y, Li N, et al. Calcitonin gene-related peptide: A possible biomarker in migraine patients with patent foramen ovale[J]. BMC Neurol, 2024, 24(1):126. doi:10.1186/s12883-024-03615-1. pmid: 38627623
[24]	Grodzka O, Borończyk M, Zduńska A, et al. Migraine and patent foramen ovale: Correlation, coexistence, dependence. A narrative review[J]. Headache, 2026, 66(1):307-321. doi:10.1111/head.15067.
[25]	Thanopoulos BVD, Bompotis GC, Deleanou D, et al. Transcatheter closure of patent foramen ovale using the cocoon occluder: A multicenter retrospective study[J]. Hellenic J Cardiol, 2023, 75:21-25. doi:10.1016/j.hjc.2023.04.011.
[26]	Sun L, Fan Z, Gao J, et al. Association between patent foramen ovale morphology and clinical outcomes following transcatheter closure[J]. Int J Cardiol, 2024, 412:132307. doi:10.1016/j.ijcard.2024.132307.
[27]	Rizza V, Belli M, Stella S, et al. A ‘twice closed’ patent foramen ovale: A case report of percutaneous management of a residual interatrial shunt in a patient with persistent migraine symptoms[J]. Eur Heart J Case Rep, 2024, 8(9):ytae449. doi:10.1093/ehjcr/ytae449.
[28]	Iannetta L, Presbitero P, Onorato EM, et al. Clinical implications of residual shunt after patent foramen ovale closure[J]. Minerva Cardiol Angiol, 2025, 73(3):355-366. doi:10.23736/S2724-5683.24.06456-1.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 28

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ding Qiufen, Yang Zhenyu, Li Cuiqin, Wang Jian. Correlation between myocardial bridge of the left anterior descending coronary artery and parameters of its proximal perivascular adipose tissue [J]. Clinical Focus, 2026, 41(4): 307-311.
[2]	. [J]. Clinical Focus, 2025, 40(2): 172-179.
[3]	Liu Duo, Li Yanling, Guo Zhaoxia, Li Jianfeng, Zhang Huijuan, Xie Ping. Anomalous left coronary artery from the pulmonary artery: A case report and literature review [J]. Clinical Focus, 2023, 38(7): 618-622.
[4]	Zhang Xueqian, Li Yang, Xu Guodong, Lyu Peiyuan. Analysis of demographic, clinical and imaging in patients with acute cerebral infarction caused by patent foramen ovale [J]. Clinical Focus, 2023, 38(6): 500-503.
[5]	Ren Ling, Jiang Shan. Relationship between serum amyloid A, high sensitive C-reactive protein, nitric oxide and adverse cardiovascular events in patients with stable coronary heart disease [J]. Clinical Focus, 2021, 36(1): 16-20.
[6]	Chen Junhui, Su Peng, Liu Shurao, Gao Xia,Song Pan, Yang Jianping. Effect of angiotensin converting enzyme inhibitor or angiotensin Ⅱ receptor blocker on right ventricular structure and function in transposition of great arteries with intra-atrial baffle: a meta-analysis [J]. Clinical Focus, 2016, 31(3): 307-314.
[7]	. [J]. Clinical Focus, 2015, 30(9): 1061-1062.
[8]	. Study on atrioventricular junction structural anomalies in patients with transposition of great arteries using 256-slice spiral CT [J]. Clinical Focus, 2015, 30(7): 769-772.
[9]	Zhang Gejun;Xu Zhongying;Jiang Shiliang;Zhao Shihua;Ling Jian;Song Huijun;Wan Junyi. Efficiency evaluation of retrograde transcatheter closure of ventricular septal defects using amplatzer duct occluder Ⅱ [J]. Clinical Focus, 2015, 30(6): 601-604.
[10]	ZHANG Ge-jun;LING Jian;JIANG Shi-liang;XU Zhong-ying;ZHAO Shi-hua;ZHENG Hong;SONG Hui-jun;JIN Jing-lin. Transcatheter intervention of residual pulmonary stenosis after surgical correction of Tetralogy of Fallot and efficiency evaluation [J]. Clinical Focus, 2014, 29(6): 634-636.
[11]	YIN Ren-lin;JIANG Ting-bo;XUE Feng;HE Zhi-song. Correlation between mean platelet volume and coronary collateral circulation formation in patients with acute coronary syndrome [J]. CLINICAL FOCUS, 2014, 29(2): 138-140.
[12]	TIAN Xiao-yu;CHEN Hui-fen;YANG Shi-bin;TIAN Chang-hai;WANG Xiao-ning;ZHANG Hui-feng. Impact factors on plasma levels of B-type natriuretic peptide in children with congenital heart disease in perioperative period [J]. CLINICAL FOCUS, 2013, 28(10): 1107-1.10911e+007.
[13]	. [J]. Clinical Focus, 2013, 28(1): 110-112.
[14]	. [J]. Clinical Focus, 2012, 27(21): 1889-1891.
[15]	. [J]. Clinical Focus, 2012, 27(20): 1812-1813.